123 related articles for article (PubMed ID: 18753823)
21. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
22. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
23. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
24. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
[TBL] [Abstract][Full Text] [Related]
26. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
27. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
Kasamon YL; Wahl RL
Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Osieka R; Buell U
Nucl Med Commun; 1998 Nov; 19(11):1055-63. PubMed ID: 9861622
[TBL] [Abstract][Full Text] [Related]
29. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
Karantanis D; O'eill BP; Subramaniam RM; Witte RJ; Mullan BP; Nathan MA; Lowe VJ; Peller PJ; Wiseman GA
Nucl Med Commun; 2007 Nov; 28(11):834-41. PubMed ID: 17901765
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
[TBL] [Abstract][Full Text] [Related]
32. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
33. Lymphadenopathy resulting from acute toxoplasmosis mimicking relapse of non-Hodgkin's lymphoma on fluorodeoxyglucose positron emission tomography/computed tomography.
Joshi P; Lele V; Mahajan P
J Cancer Res Ther; 2012; 8(1):126-8. PubMed ID: 22531531
[TBL] [Abstract][Full Text] [Related]
34. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
35. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
[TBL] [Abstract][Full Text] [Related]
37. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
38. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
Fuster D; Chiang S; Andreadis C; Guan L; Zhuang H; Schuster S; Alavi A
Nucl Med Commun; 2006 Jan; 27(1):11-5. PubMed ID: 16340718
[TBL] [Abstract][Full Text] [Related]
39. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA
Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102
[TBL] [Abstract][Full Text] [Related]
40. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.
Fanti S; Castellucci P; Stefoni V; Nanni C; Tani M; Rubello D; Ambrosini V; Zinzani PL; Franchi R
Ann Nucl Med; 2008 Jun; 22(5):429-32. PubMed ID: 18600422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]